4.4 Article

Characterization of Patients With and Without Painful Peripheral Neuropathy After Receiving Neurotoxic Chemotherapy: Traditional Quantitative Sensory Testing vs C-Fiber and Aδ-Fiber Selective Diode Laser Stimulation

期刊

JOURNAL OF PAIN
卷 23, 期 5, 页码 796-809

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.jpain.2021.11.011

关键词

DLss stimulation; QST; painful CIPN; peripheral neuropathy; neuropathic pain

资金

  1. National Institutes of Health [NIH NCI Phase 1 SBIR funding] [1R43CA206796-01A1]

向作者/读者索取更多资源

Chemotherapy induced peripheral neuropathy (CIPN) is a common complication of chemotherapy and lacks early detection methods and specific biomarkers. This study compared DLss and QST in identifying differences between patients with painful CIPN and a control group.
Painful chemotherapy induced peripheral neuropathy (CIPN) is a common complication of chemotherapy with drugs such as taxanes and platinum compounds. Currently, no methods are available for early detection of sensory changes that are associated with painful CIPN, nor are there biomarkers that are specific to painful CIPN. This study aimed to compare Diode Laser fiber type-selective stimulator (DLss), a method to selectively stimulate cutaneous C and A delta fibers, to traditional quantitative sensory testing (QST) in determining psychophysical differences between patients with painful CIPN and a control group. Sensory testing was performed on the dorsal mid-foot of 20 patients with painful neuropathy after taxane- or platinum-based chemotherapy, and 20 patients who received similar neurotoxic chemotherapy, without painful CIPN. In a multivariable analysis, C-fiber to A delta fiber detection threshold ratio, measured by DLss, was significantly different between the groups (P <.05). While QST parameters such as warmth detection threshold were different between the groups in univariate analyses, these findings were likely attributable to group differences in patient age and cumulative chemotherapy dose. Perspective: In this study, fiber-specific DLss test showed potential in identifying sensory changes that are specific for painful neuropathy, encouraging future testing of this approach as a biomarker for early detection of painful CIPN. (C) 2021 by United States Association for the Study of Pain, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据